| A) | These proteins can affect pharmacokinetics. | ||
| B) | Breast cancer resistance protein moves drugs into the liver. | ||
| C) | Most available data are related to organic anion transporting polypeptides. | ||
| D) | It is rare for medications to impact P-gp and CYP450. |
Pharmacokinetics can also be affected by drug transporters (e.g., P-glycoprotein, breast cancer resistance protein [BCRP], multidrug and toxin excluders [MATEs], organic anion transporting polypeptides [OATPs]). All of these proteins help move medications into or out of cells, which can impact drug absorption, distribution, or elimination [3; 5].
| A) | BCRP | ||
| B) | MATEs | ||
| C) | OATPs | ||
| D) | P-gp |
We are still learning about the significance of these transporters on pharmacokinetics. Most of the available data are related to P-glycoprotein (P-gp, multidrug resistance protein 1 [MDR1]). P-gp is a drug efflux pump found in the gut, liver, kidney, blood-brain barrier, and cancer cells. It pumps drugs out of cells and into the gut, bile, and/or urine for excretion [6]. Other examples include BCRP, which pumps drugs out of cells in the gut, liver, and kidney, and OATPs (e.g., OATP1B1, OATP1B3), which move drugs into the liver [5].
| A) | Apixaban and dabigatran | ||
| B) | Edoxaban and rivaroxaban | ||
| C) | Apixaban and rivaroxaban | ||
| D) | Edoxaban and dabigatran |
Generally, CYP450 interactions and drug transporter interactions involve substrates, inhibitors, and inducers. Inhibitors may increase levels of CYP450 or P-gp substrates, and inducers may decrease levels of CYP450 or P-gp substrates. For many interactions, CYP450 enzyme inhibition or induction is also involved, and P-glycoprotein substrates are often also CYP3A4 substrates, so the contribution of P-gp inhibition/induction versus CYP450 inhibition/induction can be difficult to discern [7,8,9]. For example, apixaban and rivaroxaban are metabolized by CYP3A4 (Table 1), and absorption of all DOACs is affected by P-glycoprotein (Table 2) [2,10].
| A) | Nafcillin | ||
| B) | Oxcarbazepine | ||
| C) | Rifabutin | ||
| D) | Voriconazole |
SELECT CYP450-3A4 PATHWAY DRUG INTERACTIONS
| DOAC Substratesc | Select Inhibitors | Select Inducers | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| A) | Amiodarone | ||
| B) | Diltiazem | ||
| C) | Erythromycin | ||
| D) | Phenytoin |
SELECT P-GLYCOPROTEIN DRUG INTERACTIONS
| DOAC Substrates | Select Inhibitors | Select Inducersa | |||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
| |||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||
| A) | Rifampin | ||
| B) | Ritonavir | ||
| C) | Ranolazine | ||
| D) | Famotidine |
Drug experts from Pharmacist's Letter and Prescriber Insights provide the following practical approach to managing DOAC interactions [11]:
Pinpoint critical DOAC interactions, and act if necessary.
Generally avoid combining DOACs with strong CYP3A4 and P-glycoprotein inducers (e.g., phenytoin, rifampin, St. John's wort). These may lower DOAC levels and increase thrombosis risk.
If these interacting medications cannot be avoided, switch to warfarin, because it is easier to monitor than a DOAC.
Watch for strong CYP3A4 and P-glycoprotein inhibitors (e.g., ritonavir, itraconazole), as these may raise DOAC levels and increase bleeding risk.
| A) | Itraconazole | ||
| B) | Levofloxacin | ||
| C) | Phenytoin | ||
| D) | Famotidine |
Drug experts from Pharmacist's Letter and Prescriber Insights provide the following practical approach to managing DOAC interactions [11]:
Pinpoint critical DOAC interactions, and act if necessary.
Generally avoid combining DOACs with strong CYP3A4 and P-glycoprotein inducers (e.g., phenytoin, rifampin, St. John's wort). These may lower DOAC levels and increase thrombosis risk.
If these interacting medications cannot be avoided, switch to warfarin, because it is easier to monitor than a DOAC.
Watch for strong CYP3A4 and P-glycoprotein inhibitors (e.g., ritonavir, itraconazole), as these may raise DOAC levels and increase bleeding risk.
| A) | All DOACs should be held during treatment with nirmatrelvir/ritonavir. | ||
| B) | Nirmatrelvir/ritonavir may be a concern with DOACs because it inhibits CYP3A4 and P-gp. | ||
| C) | DOAC doses should generally be increased during treatment with nirmatrelvir/ritonavir. | ||
| D) | Nirmatrelvir/ritonavir may be a concern with DOACs because it induces CYP1A2 and P-gp. |
To manage these drug interactions, consider the specific DOAC, dose, and indication (Table 3). One example that blends consideration of these factors is use of nirmatrelvir/ritonavir for treatment of COVID-19 in patients receiving a DOAC. This combination introduces potential risk for drug interactions, because ritonavir is a strong CYP3A4 and P-glycoprotein inhibitor. For instance, when a patient is receiving nirmatrelvir/ritonavir for COVID-19, apixaban being given for atrial fibrillation should be reduced by 50% (e.g., from 5 mg to 2.5 mg twice per day) during treatment and for three days after; if the patient is already taking 2.5 mg twice per day, coadministration should be avoided. In contrast, coadministration of nirmatrelvir/ritonavir and rivaroxaban should be avoided [12].
| A) | Reduce the apixaban dose by 50%. | ||
| B) | Change apixaban to rivaroxaban. | ||
| C) | Change apixaban to warfarin. | ||
| D) | Continue apixaban at the standard dose. |
Drug experts from Pharmacist's Letter and Prescriber Insights provide the following practical approach to managing DOAC interactions [11]:
Pinpoint critical DOAC interactions, and act if necessary.
Generally avoid combining DOACs with strong CYP3A4 and P-glycoprotein inducers (e.g., phenytoin, rifampin, St. John's wort). These may lower DOAC levels and increase thrombosis risk.
If these interacting medications cannot be avoided, switch to warfarin, because it is easier to monitor than a DOAC.
Watch for strong CYP3A4 and P-glycoprotein inhibitors (e.g., ritonavir, itraconazole), as these may raise DOAC levels and increase bleeding risk.
| A) | Continue apixaban and aspirin. | ||
| B) | Stop aspirin. | ||
| C) | Change aspirin to clopidogrel. | ||
| D) | Reduce the apixaban dose by 50%. |
Caution should be exercised when prescribing a DOAC with medications that increase the risk of bleeding (e.g., antiplatelets, nonsteroidal anti-inflammatory drugs [NSAIDs], SSRIs/SNRIs). Ensuring the need for both agents is the first step. For example, aspirin used for cardiovascular primary prevention can usually be discontinued; aspirin for cardiovascular primary prevention is no longer routinely recommended, regardless of DOAC use [4; 13; 14]. Duration of combination therapy is another concern. For instance, clopidogrel can be discontinued one year after stent placement for most patients with atrial fibrillation on a long-term DOAC. Randomized trial data (e.g., AFIRE, EPIC-CAD) support oral anticoagulant monotherapy after this point in patients with atrial fibrillation and stable coronary artery disease, and current guidelines support discontinuing antiplatelet therapy for most of these patients [15; 17; 18; 19].